Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445113 ((S)-N-(4-(3-chlorophenyl)- thiazol-2-yl)-1-cyano-N...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445170 ((S)-1-Cyano-N-(4-(6-cyanopyridin-2-yl)thiazol-2-yl...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445171 ((S)-1-cyano-N-(4- (6-cyano-3- methylpyridin-2- yl)...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445173 ((S)-1-Cyano-N-(4-(6-cyano-5-methoxypyridin-2-yl)th...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | Purchase MCE PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445168 ((S)-1-cyano-N-methyl-N-(4- (3-(trifluoromethyl)phe...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445188 ((S)-1-cyano-N-(4-(3- ethylphenyl)thiazol-2-yl)- N-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445198 ((S)-1-cyano-N-(4- (6-cyano-3- methoxypyridin- 2-yl...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445201 ((S)-1-cyano-N-(4-(6-cyano-5-(dimethylamino)pyridin...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445203 ((S)-1-cyano-N-(4-(6-cyano-3-ethoxypyridin-2-yl)thi...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445149 ((2S,4S)-4-Fluoro-2-(4-(5-methyl-1H-pyrazol-4-yl)in...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445080 ((S)-2-(4-(5-(Trifluoromethyl)-1H-pyrazol-4-yl)indo...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445088 ((S)-2-(4-(1H-pyrrolo [2,3-b]pyridin-3- yl)indoline...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445090 ((2S,4S)-4-fluoro-2-(4-(5-(trifluoromethyl)-1H-pyra...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445158 ((S)-2-(5-(3-(trifluoro- methyl)-1H-pyrazol-4- yl)i...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445160 ((S)-2-(4-(1H-pyrrolo[2,3-b]- pyridin-4-yl)indoline...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | <100 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445137 ((S)-2-(4-(2-Aminopyridin-4-yl)indoline-1-carbonyl)...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445159 (4-(1-(cyano-L-prolyl)indolin- 4-yl)nicotinonitrile...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445145 (1-(Cyano-L-prolyl)-N-methyl-4-(1H-pyrrolo[2,3-b]py...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445163 ((S)-2-(4-(2- (methylamino)pyrimidin- 4-yl)indoline...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445165 ((S)-2-(4-(1H-pyrazolo[3,4- b]pyridin-3-yl)indoline...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445166 ((S)-2-(4-(5H-pyrrolo[2,3- b]pyrazin-7-yl)indoline-...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445167 ((S)-N-(4-(3-chloro-4- fluorophenyl)thiazol-2-yl)-1...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445169 ((S)-1-cyano-N-(4-(3- cyanophenyl)thiazol-2-yl)- N-...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445107 ((S)-1-Cyano-N-(4-(2-methoxyphenyl)thiazol-2-yl)-N-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445108 ((S)-1-cyano-N-(4-(3- methoxyphenyl)thiazol-2- yl)-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445122 ((S)-N-(4-(4- chlorophenyl)thiazol- 2-yl)-1-cyano-N...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445138 ((S)-1-cyano-N-(4-(2- cyanopyridin-4- yl)thiazol-2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445139 ((S)-1-cyano-N-(4- (4-cyanopyridin-2- yl)thiazol-2-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445172 ((S)-1-cyano-N- methyl-N-(4-(6- (trifluoromethyl)- ...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445174 ((S)-1-Cyano-N-(4-(6-cyano-5-methylpyridin-2-yl)thi...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445148 ((S)-2-(6-(5-Methyl-4H-1,2,4-triazol-3-yl)-4-phenyl...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445175 ((S)-2-(4-(4-Cyanophenyl)-6-(5-methyl-4H-1,2,4-tria...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445176 ((S)-2-(4-(3-Cyanophenyl)-6-(5-methyl-4H-1,2,4-tria...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445155 ((S)-N-(4-(3-Chlorophenyl)thiazol-2-yl)-1-cyano-N-e...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445156 ((S)-1-Cyano-N-(4-(5-cyanopyridin-3-yl) thiazol-2-y...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445187 ((S)-2-(5-(3-cyanophenyl)- isoindoline-2-carbonyl)-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445167 ((S)-N-(4-(3-chloro-4- fluorophenyl)thiazol-2-yl)-1...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445169 ((S)-1-cyano-N-(4-(3- cyanophenyl)thiazol-2-yl)- N-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445194 ((S)-2-(5-(3-nitrophenyl)- isoindoline-2-carbonyl)-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445197 ((S)-1-cyano-N-methyl-N-(4-(3-(N-methylmethylsulfon...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445200 ((S)-1-cyano-N-(4-(6-cyano-5-ethoxypyridin-2-yl)thi...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445202 ((S)-1-cyano-N-(4-(6-cyano-3-(2-methoxyethoxy)pyrid...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445204 ((S)-1-cyano-N-(4-(6-cyanopyridin-2-yl)-5-ethylthia...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445205 ((S)-1-cyano-N-(4-(6-cyanopyridin-2-yl)-5-methylthi...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445206 ((S)-1-cyano-N-(4-(3-(methoxymethyl)phenyl)thiazol-...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase 30 (Homo sapiens (Human)) | BDBM445208 ((S)-1-cyano-N-(4-(6-cyclopropylpyridin-2-yl)thiazo...) | PDB UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 μM) in 50% DMSO in a 96-well po... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445150 (N-(4-(1-(Cyano-L-prolyl)indolin-4-yl)pyridin-2-yl)...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445151 ((S)-2-(4-(5-(Trifluoromethyl)-1H-pyrazol-4-yl)-2,3...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445081 ((S)-2-(4-(1H-Pyrazol-4-yl)indoline-1-carbonyl)pyrr...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair | |||||||||||||
Ubiquitin carboxyl-terminal hydrolase isozyme L1 (Homo sapiens (Human)) | BDBM445082 ((S)-2-(4-(5-Methyl-1H-pyrazol-4-yl)indoline-1-carb...) | PDB MMDB KEGG UniProtKB/SwissProt B.MOAD antibodypedia GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 550 | n/a | n/a | n/a | n/a | n/a | n/a |
MISSION THERAPEUTICS LIMITED US Patent | Assay Description Dilution plates were prepared at 21 times the final concentration (2100 μM for a final concentration of 100 (μM) in 50% DMSO in a 96-well p... | US Patent US10669234 (2020) BindingDB Entry DOI: 10.7270/Q22N559S | |||||||||||
More data for this Ligand-Target Pair |
Displayed 1 to 50 (of 193 total ) | Next | Last >> |